Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05662865 · ClinicalTrials.gov registry record · Phase 1
Low-CArbohydrate Diet and SGLT2-INhibitOr to Achieve Moderate Ketosis in Healthy Volunteers
A Phase 1 study of Ketones, Metabolism, sponsored by AdventHealth Translational Research Institute.
- Active
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT05662865 is a Phase 1 study of Ketones, Metabolism that is active but no longer recruiting, run by AdventHealth Translational Research Institute. The registered enrollment target is 9 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05662865, a Phase 1 study of Ketones, Metabolism, is active but no longer recruiting, sponsored by AdventHealth Translational Research Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to help us better understand how plasma ketones respond to a low-carb diet when combined with an SGLT2 inhibitor.
Conditions Studied
Interventions
- DRUG SGLT2 inhibitor
- OTHER Controlled, Adaptive Study Diet
Study Locations (1)
Florida
- AdventHealth Translational Research Institute - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2023-03-16 |
| Est. Completion | 2025-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05662865
The ClinicalTrials.gov registry entry for NCT05662865 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AdventHealth Translational Research Institute, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ketones, Metabolism appearing as the primary indexed condition, and to 2 interventions - of which SGLT2 inhibitor is the first listed.
NCT05662865 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT05662865 about?
NCT05662865 is a clinical study titled "Low-CArbohydrate Diet and SGLT2-INhibitOr to Achieve Moderate Ketosis in Healthy Volunteers". The purpose of this study is to help us better understand how plasma ketones respond to a low-carb diet when combined with an SGLT2 inhibitor.
What is the current status of trial NCT05662865?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2023-03-16. Estimated completion is 2025-12.
What conditions does trial NCT05662865 study?
This clinical trial studies the following conditions: Ketones, Metabolism.
What interventions are being tested in trial NCT05662865?
The interventions under investigation include: SGLT2 inhibitor (DRUG), Controlled, Adaptive Study Diet (OTHER).
Who is sponsoring clinical trial NCT05662865?
This trial is sponsored by AdventHealth Translational Research Institute, which has 54 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05662865 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ketones, Metabolism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.